Cipla Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 30, 2025, 10:15 am

Quick Insight

Cipla Ltd, a prominent player in the pharmaceutical industry, currently trades at a price of ₹1,561 with a market capitalization of ₹1,26,165 Cr. The company's financial metrics reveal a price-to-earnings ratio of 23.5, indicating investors are willing to pay a premium for its earnings. Moreover, Cipla demonstrates robust returns on equity (ROE) at 17.8% and returns on capital employed (ROCE) at 22.7%, reflecting efficient use of capital. With a healthy operating profit margin of 26% and a strong interest coverage ratio of 78.30x, Cipla exhibits sound financial health and operational efficiency. The diverse shareholding pattern, including significant stakes held by promoters, FIIs, and DIIs, underscores confidence in the company. Overall, Cipla's solid financial performance and market position suggest a favorable outlook for potential investors.

Competitors of Cipla Ltd

All Competitor Stocks of Cipla Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:40 pm

Below is a detailed analysis of the quarterly data for Cipla Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 6,957.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,730.00 Cr. (Mar 2025) to 6,957.00 Cr., marking an increase of 227.00 Cr..
• For Expenses, as of Jun 2025, the value is 5,179.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5,192.00 Cr. (Mar 2025) to 5,179.00 Cr., marking a decrease of 13.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 1,778.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,538.00 Cr. (Mar 2025) to 1,778.00 Cr., marking an increase of 240.00 Cr..
• For OPM %, as of Jun 2025, the value is 26.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Mar 2025) to 26.00%, marking an increase of 3.00%.
• For Other Income, as of Jun 2025, the value is 259.00 Cr.. The value appears to be declining and may need further review. It has decreased from 289.00 Cr. (Mar 2025) to 259.00 Cr., marking a decrease of 30.00 Cr..
• For Interest, as of Jun 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
• For Depreciation, as of Jun 2025, the value is 253.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 309.00 Cr. (Mar 2025) to 253.00 Cr., marking a decrease of 56.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 1,770.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,504.00 Cr. (Mar 2025) to 1,770.00 Cr., marking an increase of 266.00 Cr..
• For Tax %, as of Jun 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 19.00% (Mar 2025) to 27.00%, marking an increase of 8.00%.
• For Net Profit, as of Jun 2025, the value is 1,292.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,214.00 Cr. (Mar 2025) to 1,292.00 Cr., marking an increase of 78.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 16.06. The value appears strong and on an upward trend. It has increased from 15.13 (Mar 2025) to 16.06, marking an increase of 0.93.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 6:58 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 3:24 pm

Below is a detailed analysis of the balance sheet data for Cipla Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 162.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Mar 2024) to 162.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 31,032.00 Cr.. The value appears strong and on an upward trend. It has increased from 26,545.00 Cr. (Mar 2024) to 31,032.00 Cr., marking an increase of 4,487.00 Cr..
• For Borrowings, as of Mar 2025, the value is 438.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 559.00 Cr. (Mar 2024) to 438.00 Cr., marking a decrease of 121.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 5,702.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5,267.00 Cr. (Mar 2024) to 5,702.00 Cr., marking an increase of 435.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 37,334.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32,533.00 Cr. (Mar 2024) to 37,334.00 Cr., marking an increase of 4,801.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 10,006.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,607.00 Cr. (Mar 2024) to 10,006.00 Cr., marking an increase of 399.00 Cr..
• For CWIP, as of Mar 2025, the value is 1,566.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,153.00 Cr. (Mar 2024) to 1,566.00 Cr., marking an increase of 413.00 Cr..
• For Investments, as of Mar 2025, the value is 7,933.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,449.00 Cr. (Mar 2024) to 7,933.00 Cr., marking an increase of 2,484.00 Cr..
• For Other Assets, as of Mar 2025, the value is 17,828.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,323.00 Cr. (Mar 2024) to 17,828.00 Cr., marking an increase of 1,505.00 Cr..
• For Total Assets, as of Mar 2025, the value is 37,334.00 Cr.. The value appears strong and on an upward trend. It has increased from 32,533.00 Cr. (Mar 2024) to 37,334.00 Cr., marking an increase of 4,801.00 Cr..

Notably, the Reserves (31,032.00 Cr.) exceed the Borrowings (438.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Cipla Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 51.05. This value is within the healthy range. It has increased from 34.72 (Mar 23) to 51.05, marking an increase of 16.33.
• For Diluted EPS (Rs.), as of Mar 24, the value is 51.01. This value is within the healthy range. It has increased from 34.69 (Mar 23) to 51.01, marking an increase of 16.32.
• For Cash EPS (Rs.), as of Mar 24, the value is 64.49. This value is within the healthy range. It has increased from 49.65 (Mar 23) to 64.49, marking an increase of 14.84.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 331.98. It has increased from 293.79 (Mar 23) to 331.98, marking an increase of 38.19.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 331.98. It has increased from 293.79 (Mar 23) to 331.98, marking an increase of 38.19.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 319.24. It has increased from 281.89 (Mar 23) to 319.24, marking an increase of 37.35.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 87.17. This value is within the healthy range. It has increased from 68.17 (Mar 23) to 87.17, marking an increase of 19.00.
• For PBIT / Share (Rs.), as of Mar 24, the value is 74.15. This value is within the healthy range. It has increased from 53.65 (Mar 23) to 74.15, marking an increase of 20.50.
• For PBT / Share (Rs.), as of Mar 24, the value is 70.62. This value is within the healthy range. It has increased from 50.03 (Mar 23) to 70.62, marking an increase of 20.59.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 51.47. This value is within the healthy range. It has increased from 35.13 (Mar 23) to 51.47, marking an increase of 16.34.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 51.05. This value is within the healthy range. It has increased from 34.71 (Mar 23) to 51.05, marking an increase of 16.34.
• For PBDIT Margin (%), as of Mar 24, the value is 27.30. This value is within the healthy range. It has increased from 24.18 (Mar 23) to 27.30, marking an increase of 3.12.
• For PBIT Margin (%), as of Mar 24, the value is 23.22. This value exceeds the healthy maximum of 20. It has increased from 19.03 (Mar 23) to 23.22, marking an increase of 4.19.
• For PBT Margin (%), as of Mar 24, the value is 22.12. This value is within the healthy range. It has increased from 17.74 (Mar 23) to 22.12, marking an increase of 4.38.
• For Net Profit Margin (%), as of Mar 24, the value is 16.12. This value exceeds the healthy maximum of 10. It has increased from 12.46 (Mar 23) to 16.12, marking an increase of 3.66.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 15.99. This value is within the healthy range. It has increased from 12.31 (Mar 23) to 15.99, marking an increase of 3.68.
• For Return on Networth / Equity (%), as of Mar 24, the value is 15.43. This value is within the healthy range. It has increased from 11.96 (Mar 23) to 15.43, marking an increase of 3.47.
• For Return on Capital Employeed (%), as of Mar 24, the value is 21.79. This value is within the healthy range. It has increased from 17.78 (Mar 23) to 21.79, marking an increase of 4.01.
• For Return On Assets (%), as of Mar 24, the value is 12.59. This value is within the healthy range. It has increased from 9.50 (Mar 23) to 12.59, marking an increase of 3.09.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.82. It has increased from 0.57 (Mar 23) to 0.82, marking an increase of 0.25.
• For Current Ratio (X), as of Mar 24, the value is 3.71. This value exceeds the healthy maximum of 3. It has increased from 3.38 (Mar 23) to 3.71, marking an increase of 0.33.
• For Quick Ratio (X), as of Mar 24, the value is 2.71. This value exceeds the healthy maximum of 2. It has increased from 2.37 (Mar 23) to 2.71, marking an increase of 0.34.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.00. This value is below the healthy minimum of 4. It has increased from 0.81 (Mar 23) to 1.00, marking an increase of 0.19.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 16.64. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 23) to 16.64, marking an increase of 16.64.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 13.26. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 23) to 13.26, marking an increase of 13.26.
• For Earning Retention Ratio (%), as of Mar 24, the value is 83.36. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 83.36, marking an increase of 83.36.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 86.74. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 86.74, marking an increase of 86.74.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 78.30. This value is within the healthy range. It has increased from 50.23 (Mar 23) to 78.30, marking an increase of 28.07.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 49.40. This value is within the healthy range. It has increased from 28.55 (Mar 23) to 49.40, marking an increase of 20.85.
• For Enterprise Value (Cr.), as of Mar 24, the value is 120,138.52. It has increased from 71,957.46 (Mar 23) to 120,138.52, marking an increase of 48,181.06.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.66. This value exceeds the healthy maximum of 3. It has increased from 3.16 (Mar 23) to 4.66, marking an increase of 1.50.
• For EV / EBITDA (X), as of Mar 24, the value is 17.07. This value exceeds the healthy maximum of 15. It has increased from 13.08 (Mar 23) to 17.07, marking an increase of 3.99.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.68. This value exceeds the healthy maximum of 3. It has increased from 3.19 (Mar 23) to 4.68, marking an increase of 1.49.
• For Retention Ratios (%), as of Mar 24, the value is 83.35. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 83.35, marking an increase of 83.35.
• For Price / BV (X), as of Mar 24, the value is 4.52. This value exceeds the healthy maximum of 3. It has increased from 3.11 (Mar 23) to 4.52, marking an increase of 1.41.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.68. This value exceeds the healthy maximum of 3. It has increased from 3.19 (Mar 23) to 4.68, marking an increase of 1.49.
• For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness